Evidence map›Paper›PMID 41243448›Full record

Trial reportGut microbes2025

2'-Fucosyllactose supplementation results in a transient improvement in gut microbial resilience after vancomycin use in adults with overweight or obesity: a randomized, double-blind, placebo-controlled intervention.

Lars M M Vliex, David Barnett, Elena Monzel, Arjen Nauta, Guy J Oudhuis, Marina Fassarella, Jens J Holst, Erwin G Zoetendal, John Penders, Ellen E Blaak

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Gut microbes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Lars M M VliexDepartment of Human Biology, NUTRIM Institute of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center+, Maastricht, The Netherlands.
David BarnettDepartment of Medical Microbiology, Infectious Diseases and Infection Prevention, NUTRIM Institute of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center+, Maastricht, The Netherlands.ORCID 0000-0003-1961-7206
Elena MonzelDepartment of Human Biology, NUTRIM Institute of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center+, Maastricht, The Netherlands.ORCID 0000-0003-3737-6039
Arjen NautaFrieslandCampina, Amersfoort, The Netherlands.
Guy J OudhuisDepartment of Medical Microbiology, Infectious Diseases and Infection Prevention, NUTRIM Institute of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center+, Maastricht, The Netherlands.
Marina FassarellaLaboratory of Microbiology, Wageningen University & Research, Wageningen, The Netherlands.
Jens J HolstThe NovoNordisk Foundation Center for Basic Metabolic Research and Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0001-6853-3805
Erwin G ZoetendalLaboratory of Microbiology, Wageningen University & Research, Wageningen, The Netherlands.ORCID 0000-0002-7149-0727
John PendersDepartment of Medical Microbiology, Infectious Diseases and Infection Prevention, NUTRIM Institute of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center+, Maastricht, The Netherlands.ORCID 0000-0001-9146-5919
Ellen E BlaakDepartment of Human Biology, NUTRIM Institute of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center+, Maastricht, The Netherlands.ORCID 0000-0002-2496-3464

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibiotic-induced perturbations of the gut microbiome can be long-lasting and potentially affect host metabolic health. Strategies supporting microbial resilience are needed to mitigate the negative impact of antibiotics. We investigated the potential of 2'-fucosyllactose (2'-FL) supplementation after vancomycin use in a double-blind placebo-controlled randomized intervention among adults with overweight/obesity. Participants received oral vancomycin for seven days followed by 2'-FL or placebo for eight weeks. At baseline, after vancomycin use and after supplementation, glucose tolerance, insulin sensitivity, plasma lipids, glucagon-like peptide 1, inflammatory cytokines, fecal short-chain fatty acids (SCFAs) and branched-chain fatty acids were analyzed. Gut microbial diversity, composition and resilience were analyzed using 16S rRNA gene sequencing. Vancomycin use decreased gut microbial richness and diversity and disrupted microbiota composition and fecal SCFA concentrations. 2'-FL improved gut microbial resilience compared to placebo (

Indexed as

Anti-Bacterial AgentsGastrointestinal MicrobiomeObesityOverweightTrisaccharidesVancomycinAdultBacteriaDietary SupplementsDouble-Blind MethodFatty Acids, VolatileFecesFemaleHumansMaleMiddle Aged2'-fucosyllactoseAnti-Bacterial AgentsFatty Acids, VolatileRNA, Ribosomal, 16STrisaccharidesVancomycinantibioticsGut microbiomemetabolic healthprebiotics

Identifiers

PMID41243448
PMCPMC12629329

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.